Portland, OR -- (SBWIRE) -- 09/21/2017 -- Sleep disorder or insomnia is a medical disorder in which the patient has difficulty with sleep maintenance or sleep initiation. This disorder causes irregular mental, physical, social, and emotional functions.
Early buyers will receive 20% customization on this report
Factors such as increasing incidences of depression & other medical disorders, late night working schedule, busy lifestyle, lack of quality sleep, and rising geriatric population drive the market growth. However, patent expirations of major sleep disorder treatment drugs and side effects associated with these drugs such as restlessness & nausea restrain the market growth. Moreover, introduction of home sleep test kits and utilization of wearable monitors & continuous positive airway pressure (CPAP) therapy increase opportunities for the market growth.
The sleep disorder treatment drugs market is segmented on the basis of sleep disorder, product, medication, and region. On the basis of sleep disorder, it is segmented into insomnia, sleep apnea, restless legs syndrome, narcolepsy, and sleep walking. On the basis of product, it is segmented into mattresses & pillows, sleep laboratories, medications, and sleep apnea devices. On the basis of medication, it is segmented into prescription-based drugs, OTC drugs, and herbal drugs. Geographically, the market has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Get PDF of this Report @ https://www.alliedmarketresearch.com/request-toc-and-sample/4190
The key players in the market include Pfizer Inc, Sanofi, Merck & Co Inc, GlaxoSmithKline plc, Koninklijke Philips N.V., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cardinal Health, Becton Dickson and Company, and Natus Medical Incorporated.